Related Experiment Video
Updated: Mar 14, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Bombesin-Targeted PET of Prostate Cancer
Rosalba Mansi1, Ryogo Minamimoto2, Helmut Mäcke1
1Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, Germany.
Abstract:
Imaging plays an important role in prostate cancer (PC), including accurate evaluation of the extent of disease, assessment of sites of recurrent disease, and monitoring of response to treatment. Molecular imaging techniques are among the novel developments related to the imaging of PC, and various SPECT and PET radiopharmaceuticals are now available in clinical trials or commercially. Here we describe the preclinical and clinical use of gastrin-releasing peptide receptors as targets for the imaging of PC, with a focus on the development of PET tracers for the imaging of gastrin-releasing peptide receptor-positive tumors.
Insights
Gastrin-releasing peptide receptors show promise for imaging prostate cancer (PC). New positron emission tomography (PET) tracers are being developed to target these receptors for better PC detection and monitoring.
Area of Science:
- Oncology
- Radiology
- Molecular Imaging
Background:
- Imaging is crucial for prostate cancer (PC) management, including staging, recurrence detection, and treatment response assessment.
- Molecular imaging, utilizing SPECT and PET radiopharmaceuticals, represents a significant advancement in PC imaging.
- Gastrin-releasing peptide receptors (GRPR) are increasingly recognized as potential targets for PC imaging.
Purpose of the Study:
- To review the preclinical and clinical applications of gastrin-releasing peptide receptors (GRPR) as imaging targets in prostate cancer (PC).
- To highlight the development of novel positron emission tomography (PET) tracers for GRPR-positive PC tumors.
Main Methods:
- Review of preclinical studies investigating GRPR expression in PC models.
- Analysis of clinical data from studies using GRPR-targeted imaging agents.
- Focus on the development and validation of PET tracers for GRPR-positive PC.
Main Results:
- Gastrin-releasing peptide receptors (GRPR) are expressed in a significant proportion of prostate cancer (PC) tumors.
- Preclinical and early clinical data suggest GRPR-targeted imaging can accurately detect and stage PC.
- Development of novel PET tracers shows potential for improved sensitivity and specificity in PC imaging.
Conclusions:
- Gastrin-releasing peptide receptors (GRPR) are a viable molecular target for advanced prostate cancer (PC) imaging.
- Positron emission tomography (PET) tracers targeting GRPR offer a promising new tool for PC diagnosis, staging, and monitoring.
- Further clinical validation is ongoing to establish the role of GRPR-targeted PET in routine PC management.
